1
|
Vaskó B, Juhász V, Tóth B, Kurunczi A, Fekete Z, Krisjanis Zolnerciks J, Kis E, Magnan R, Bidon-Chanal Badia A, Pastor-Anglada M, Hazai E, Bikadi Z, Fülöp F, Krajcsi P. Inhibitor selectivity of CNTs and ENTs. Xenobiotica 2018; 49:840-851. [PMID: 30022699 DOI: 10.1080/00498254.2018.1501832] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
The concentrative nucleoside transporters (CNT; solute carrier family 28 (SLC28)) and the equilibrative nucleoside transporters (ENT; solute carrier family 29 (SLC29)) are important therapeutic targets but may also mediate toxicity or adverse events. To explore the relative role of the base and the monosaccharide moiety in inhibitor selectivity we selected compounds that either harbor an arabinose moiety or a cytosine moiety, as these groups had several commercially available drug members. The screening data showed that more compounds harboring a cytosine moiety displayed potent interactions with the CNTs than compounds harboring the arabinose moiety. In contrast, ENTs showed a preference for compounds with an arabinose moiety. The correlation between CNT1 and CNT3 was good as five of six compounds displayed IC50 values within the threefold threshold and one displayed a borderline 4-fold difference. For CNT1 and CNT2 as well as for CNT2 and CNT3 only two of six IC50 values correlated and one displayed a borderline 4-fold difference. Interestingly, of the six compounds that potently interacted with both ENT1 and ENT2 only nelarabine displayed selectivity. Our data show differences between inhibitor selectivities of CNTs and ENTs as well as differences within the CNT family members.
Collapse
Affiliation(s)
| | | | - Beáta Tóth
- b SOLVO Biotechnology , Budaörs , Hungary
| | | | | | | | - Emese Kis
- a SOLVO Biotechnology , Szeged , Hungary
| | | | - Axel Bidon-Chanal Badia
- c Departament de Nutrició, Ciències de l'Alimentació i Gastronomia, Facultat de Farmàcia i Ciències de l'Alimentació and Institute of Biomedicine (IBUB), Campus de l'Alimentació de Torribera , Universitat de Barcelona , Santa Coloma de Gramenet , Spain
| | - Marçal Pastor-Anglada
- d Departament de Bioquímica i Biomedicina Molecular, Facultat de Biologia and Institute of Biomedicine (IBUB) , Universitat de Barcelona , Barcelona , Spain.,e Oncology Program , National Biomedical Research Institute on Liver and Gastrointestinal Diseases (CIBER EHD), Instituto de Salud Carlos III , Madrid , Spain
| | | | | | - Ferenc Fülöp
- g Institute of Pharmaceutical Chemistry, University of Szeged , Szeged , Hungary
| | - Peter Krajcsi
- a SOLVO Biotechnology , Szeged , Hungary.,h Department of Morphology and Physiology, Faculty of Health Sciences , Semmelweis University , Budapest , Hungary.,i Faculty of Information Technology and Bionics , Pázmány Péter Catholic University , Budapest , Hungary
| |
Collapse
|
2
|
Erdő F, Nagy I, Tóth B, Bui A, Molnár É, Tímár Z, Magnan R, Krajcsi P. Abcb1a (P-glycoprotein) limits brain exposure of the anticancer drug candidate seliciclib in vivo in adult mice. Brain Res Bull 2017. [PMID: 28629814 DOI: 10.1016/j.brainresbull.2017.06.013] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
Seliciclib displayed limited brain exposure in vivo in adult rats with mature blood-brain barrier (BBB). Selicilib was shown to be a specific substrate of human ABCB1 in vitro. To demonstrate that ABCB1/Abcb1 can limit brain exposure in vivo in mice we are showing that seliciclib is a substrate of mouse Abcb1a, the murine ABCB1 ortholog expressed in the BBB as LLC-PK-Abcb1a cells displayed an efflux ratio (ER) of 15.31±3.54 versus an ER of 1.44±0.10 in LLC-PK1-mock cells. Additionally, in the presence of LY335979, an ABCB1/Abcb1a specific inhibitor, the observed ER for seliciclib in the LLC-PK1-mMdr1a cells decreased to 1.05±0.25. To demonstrate in vivo relevance of seliciclib transport by Abcb1a mouse brain microdialysis experiments were carried out that showed that the AUCbrain/AUCblood ratio of 0.143 in anesthetized mice increased about two-fold to 0.279 in the presence of PSC833 another ABCB1/Abcb1a specific inhibitor. PSC833 also increased the brain exposure (AUCbrain) of seliciclib close to 2-fold (136 vs 242) in awake mice. In sum, Abcb1a significantly decreases seliciclib permeability in vitro and is partly responsible for limited brain exposure of seliciclib in vivo in mice.
Collapse
Affiliation(s)
- Franciska Erdő
- SOLVO Biotechnology, Középfasor 52, Szeged, 6726 Hungary; Faculty of Information Technology and Bionics, Pázmány Péter Catholic University, Práter utca 50/a, Budapest, 1083 Hungary
| | - Ildikó Nagy
- SOLVO Biotechnology, Gyár u. 2, Budaörs, 2040 Hungary
| | - Beáta Tóth
- SOLVO Biotechnology, Gyár u. 2, Budaörs, 2040 Hungary
| | - Annamária Bui
- SOLVO Biotechnology, Gyár u. 2, Budaörs, 2040 Hungary
| | - Éva Molnár
- SOLVO Biotechnology, Középfasor 52, Szeged, 6726 Hungary
| | - Zoltán Tímár
- SOLVO Biotechnology, Középfasor 52, Szeged, 6726 Hungary
| | - Rémi Magnan
- SOLVO Biotechnology, Gyár u. 2, Budaörs, 2040 Hungary
| | - Peter Krajcsi
- SOLVO Biotechnology, Gyár u. 2, Budaörs, 2040 Hungary.
| |
Collapse
|
3
|
Torres FM, Sáfár Z, Vázquez-Sánchez MA, Kurunczi A, Kis E, Magnan R, Jani M, Nicolás O, Krajcsi P. Pre-Plated Cell Lines for ADMETox Applications in the Pharmaceutical Industry. ACTA ACUST UNITED AC 2015; 65:23.8.1-23.8.23. [PMID: 26250397 DOI: 10.1002/0471140856.tx2308s65] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
Membrane transporters significantly modulate membrane permeability of endobiotics and xenobiotics, such as bile acids and drugs, respectively. Various in vitro methods have been established for both ATP-binding cassette (ABC) transporters to examine cellular efflux and uptake, and for solute carriers (SLC) to examine cellular uptake of substrates. Cell-based systems are the models of choice to test drug-transporter interactions as well as drug-drug interactions for research and regulatory purposes, albeit, for low passive permeability substrates of ABC transporters, vesicular uptake assays are also recommended. Commercially available pre-plated cells (e.g., immortalized or transfected) offer a useful alternative to in-house cell culture. Three main methods are known to manufacture pre-plated cultures: regular culture medium with vacuum seal, cryopreserved delivery, and the solid shipping media technology. The regular culture medium and the solid shipping media technologies provide ready-to-use models for end users. Models expressing a broad selection of transporters are available in pre-plated formats for absorption, distribution, metabolism, excretion, and toxicity (ADMETox) studies. Conversely, the application and utility of pre-plated cultures coupled with personal experiences have not been extensively covered in published research papers or reviews, despite availability and significant use of pre-plated products in the pharmaceutical industry. In this overview, we will briefly describe: 1) in vitro tools commonly used for ADMETox testing; 2) methods employed in manufacturing, shipment and preparation of pre-plated cell lines; 3) cell-membrane barrier models currently available in pre-plated format to reproduce passage restriction of physiological barriers to certain compounds; and 4) recommended pre-plated cell lines overexpressing uptake transporters for ADMETox applications.
Collapse
Affiliation(s)
| | - Zsolt Sáfár
- Solvo Biotechnology, Budaörs, Hungary.,shared first authorship
| | | | | | - Emese Kis
- Solvo Biotechnology, Budaörs, Hungary
| | | | | | - Oriol Nicolás
- ReadyCell S. L., Barcelona, Spain.,shared senior authorship
| | - Péter Krajcsi
- Solvo Biotechnology, Budaörs, Hungary.,shared senior authorship
| |
Collapse
|
4
|
Juhász V, Beéry E, Nagy Z, Bui A, Molnár É, Zolnerciks JK, Magnan R, Jani M, Krajcsi P. Chlorothiazide is a Substrate for the Human Uptake Transporters OAT1 and OAT3. J Pharm Sci 2013; 102:1683-7. [DOI: 10.1002/jps.23491] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2012] [Revised: 01/17/2013] [Accepted: 02/12/2013] [Indexed: 11/06/2022]
|
5
|
Magnan R, Escrieut C, Gigoux V, De K, Clerc P, Niu F, Azema J, Masri B, Cordomi A, Baltas M, Tikhonova IG, Fourmy D. Distinct CCK-2 receptor conformations associated with β-arrestin-2 recruitment or phospholipase-C activation revealed by a biased antagonist. J Am Chem Soc 2013; 135:2560-73. [PMID: 23323542 DOI: 10.1021/ja308784w] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
Abstract
Seven-transmembrane receptors (7TMRs), also termed G protein-coupled receptors (GPCRs), form the largest class of cell surface membrane receptors, involving several hundred members in the human genome. Nearly 30% of marketed pharmacological agents target 7TMRs. 7TMRs adopt multiple conformations upon agonist binding. Biased agonists, in contrast to non-biased agonists, are believed to stabilize conformations preferentially activating either G-protein- or β-arrestin-dependent signaling pathways. However, proof that cognate conformations of receptors display structural differences within their binding site where biased agonism initiates, are still lacking. Here, we show that a non-biased agonist, cholecystokinin (CCK) induces conformational states of the CCK2R activating Gq-protein-dependent pathway (CCK2R(G)) or recruiting β-arrestin2 (CCK2R(β)) that are pharmacologically and structurally distinct. Two structurally unrelated antagonists competitively inhibited both pathways. A third ligand (GV150013X) acted as a high affinity competitive antagonist on CCK2R(G) but was nearly inefficient as inhibitor of CCK2R(β). Several structural elements on both GV150013X and in CCK2R binding cavity, which hinder binding of GV150013X only to the CCK2R(β) were identified. At last, proximity between two conserved amino acids from transmembrane helices 3 and 7 interacting through sulfur-aromatic interaction was shown to be crucial for selective stabilization of the CCK2R(β) state. These data establish structural evidence for distinct conformations of a 7TMR associated with β-arrestin-2 recruitment or G-protein coupling and validate relevance of the design of biased ligands able to selectively target each functional conformation of 7TMRs.
Collapse
Affiliation(s)
- Rémi Magnan
- EA 4552, Université de Toulouse 3, 31432 Toulouse, France
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Infante MA, Humber CC, Mattson SN, Riley EP, Bryan AD, Ewing SF, Brock A, Magnan R, Hutchison K, Berglund KJ, Fahlke C, Berggren U, Zetterberg H, Blennow K, Engel J, Balldin J, Ulmer A, Lehert P, Mason B, Beaunieux H, Cauvin C, Lannuzel C, Duval C, Le Berre A, Vabret F, Pitel A, Allain P, Desgranges B, Eustache F. FREE ORAL COMMUNICATIONS 4: ALCOHOL DEPENDENCE: TREATMENT APPROACHES * O4.1 * EFFECTIVENESS OF STIMULANT MEDICATION IN FETAL ALCOHOL SPECTRUM DISORDERS. Alcohol Alcohol 2011. [DOI: 10.1093/alcalc/agr096] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
7
|
Magnan R, Masri B, Escrieut C, Foucaud M, Cordelier P, Fourmy D. Regulation of membrane cholecystokinin-2 receptor by agonists enables classification of partial agonists as biased agonists. J Biol Chem 2010; 286:6707-19. [PMID: 21156802 DOI: 10.1074/jbc.m110.196048] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Given the importance of G-protein-coupled receptors as pharmacological targets in medicine, efforts directed at understanding the molecular mechanism by which pharmacological compounds regulate their presence at the cell surface is of paramount importance. In this context, using confocal microscopy and bioluminescence resonance energy transfer, we have investigated internalization and intracellular trafficking of the cholecystokinin-2 receptor (CCK2R) in response to both natural and synthetic ligands with different pharmacological features. We found that CCK and gastrin, which are full agonists on CCK2R-induced inositol phosphate production, rapidly and abundantly stimulate internalization. Internalized CCK2R did not rapidly recycle to plasma membrane but instead was directed to late endosomes/lysosomes. CCK2R endocytosis involves clathrin-coated pits and dynamin and high affinity and prolonged binding of β-arrestin1 or -2. Partial agonists and antagonists on CCK2R-induced inositol phosphate formation and ERK1/2 phosphorylation did not stimulate CCK2R internalization or β-arrestin recruitment to the CCK2R but blocked full agonist-induced internalization and β-arrestin recruitment. The extreme C-terminal region of the CCK2R (and more precisely phosphorylatable residues Ser(437)-Xaa(438)-Thr(439)-Thr(440)-Xaa(441)-Ser(442)-Thr(443)) were critical for β-arrestin recruitment. However, this region and β-arrestins were dispensable for CCK2R internalization. In conclusion, this study allowed us to classify the human CCK2R as a member of class B G-protein-coupled receptors with regard to its endocytosis features and identified biased agonists of the CCK2R. These new important insights will allow us to investigate the role of internalized CCK2R·β-arrestin complexes in cancers expressing this receptor and to develop new diagnosis and therapeutic strategies targeting this receptor.
Collapse
Affiliation(s)
- Rémi Magnan
- INSERM, Unit 858, 12 MR, 1 Avenue Jean Poulhés, 31432 Toulouse Cedex 4, France
| | | | | | | | | | | |
Collapse
|